相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.
Mauricio Burotto et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
David Cella et al.
LANCET ONCOLOGY (2022)
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
Borje Ljungberg et al.
EUROPEAN UROLOGY (2022)
A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial
Anjali Zarkar et al.
CLINICAL GENITOURINARY CANCER (2022)
The shifting treatment paradigm of metastatic renal cell carcinoma
Yasser Ged et al.
NATURE REVIEWS UROLOGY (2022)
Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
T. Powles
ANNALS OF ONCOLOGY (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
S. Aeppli et al.
ESMO OPEN (2021)
What is the role of real-world data in metastatic renal cell cancer?
Will Ince et al.
FUTURE ONCOLOGY (2021)
Cabozantinib (cabo) combined with durvalumab (durva) in gastroesophageal (GE) cancer and other gastrointestinal (GI) malignancies: Preliminary phase Ib CAMILLA study results.
Anwaar Saeed et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial
Andrea B. Apolo et al.
LANCET ONCOLOGY (2020)
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Paulo Bergerot et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Xin Lu et al.
NATURE (2017)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
L. Zhou et al.
ONCOGENE (2016)
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
J. M. Kim et al.
ANNALS OF ONCOLOGY (2016)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
Holger Moch et al.
EUROPEAN UROLOGY (2016)
Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence
Joline S. J. Lim et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)
The Receptor Tyrosine Kinase AXL in Cancer Progression
Erinn B. Rankin et al.
CANCERS (2016)
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
D. Y. C. Heng et al.
ANNALS OF ONCOLOGY (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Daniel Y. C. Heng et al.
LANCET ONCOLOGY (2013)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
Development and validation of a scale to measure disease-related symptoms of kidney cancer
David Cella et al.
VALUE IN HEALTH (2007)
Pain: a review of three commonly used pain rating scales
A Williamson et al.
JOURNAL OF CLINICAL NURSING (2005)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
分享论文
